科学家发现NPM1蛋白质是肠道和肝癌的关键,提供了新的治疗希望。 Scientists find NPM1 protein key to bowel and liver cancers, offering new treatment hope.

英国苏格兰癌症研究所的研究人员已确定核糖核磷素(NPM1)为治疗肠道癌和肝癌的潜在目标,这种癌症的发病率正在上升,特别是在苏格兰的年轻人中。 Researchers at the Cancer Research UK Scotland Institute have identified nucleophosmin (NPM1) as a potential target for treating bowel and liver cancers, which are rising in incidence—especially among younger adults in Scotland. 高水平的NPM1,由WNT通路遗传缺陷驱动,通过破坏正常蛋白质生产和抑制瘤自然防御来维持瘤生长. High levels of NPM1, driven by WNT pathway genetic faults, help sustain tumor growth by disrupting normal protein production and suppressing natural tumor defenses. 阻断NPM1在实验室模型中减缓或阻止癌症进展,而不会损害健康的成年组织,这表明安全的向治疗. Blocking NPM1 slowed or stopped cancer progression in lab models without harming healthy adult tissues, suggesting a safe, targeted therapy. 这些结果公布在《自然遗传学》上,可能导致这些难以治疗的癌症出现新药物,并可能适用于具有类似基因错误的其他癌症。 The findings, published in Nature Genetics, could lead to new drugs for these hard-to-treat cancers and may apply to other cancers with similar genetic errors.